- Products
- Engineered cell lines
- CRISPRmod CRISPRa dCas9-VPR Stable Cell Lines
CRISPRmod CRISPRa dCas9-VPR Stable Cell Lines
Streamline CRISPR activation experiments with stably expressing dCas9-VPR cell lines
Choose from a range of common cell line backgrounds, then simply deliver CRISPRa guide RNA for straightforward gene activation.
CRISPR activation ready cells
- Generated using Horizon's own CRISPRa dCas9-VPR vectors with a Blasticidin resistance selection marker.
- QC validated to ensure stable expression and functionality of dCas9-VPR endonuclease.
- Cells are provided in a pooled format of >1 million cells per vial.
Ideal for use with other Horizon products
For individual gene activation experiments and gain-of-function studies use CRISPRa synthetic crRNA or lentiviral sgRNA. For screening projects, see our predefined gene family, druggable or whole genome CRISPRa synthetic crRNA screening libraries or use our Cherry Pick Custom Library Tool to build your own CRISPRa library.
Proven models
Our catalog of cell lines has become a gold-standard resource in antibody validation, cancer research, and early drug-discovery research. Horizon was recently recognized by CiteAb as the Cell Line Supplier to Watch in Cancer Research for 2024. Read more about the CiteAb award.
Limited use agreement
All cell lines engineered by Horizon Discovery are purchased under the terms of our Limited Use Label License.
Cell culture medium and cell line maintenance tips
Cell line background | Cat # | Basal medium | Supplements | Subculturing tips |
---|---|---|---|---|
A549 | HD Cas9-001 | RPMI 1640 | 10% FBS 1% Pen/Strep |
|
HCT-116 | HD Cas9-002 HD dCas9-VPR-002 |
RPMI1640 | 10% FBS 1% Pen/Strep |
|
Jurkat | HD Cas9-004 | RPMI1640 | 10% FBS 1% Pen/Strep |
|
K-562 | HD Cas9-005 HD dCas9-VPR-005 |
IMDM | 10% FBS 1% Pen/Strep |
|
RKO | HD Cas9-007 | RPMI1640 | 10% FBS 1% Pen/Strep |
|
NIH/3T3 | HD Cas9-010 | DMEM, high glucose, GlutaMAXTM | 10% FBS 1% Pen/Strep |
|
HAP1 | HD Cas9-011 HD dCas9-VPR-011 |
IMDM | 10% FBS 1% Pen/Strep |
|
U2OS | HD Cas9-012 HD dCas9-VPR-012 |
DMEM, high glucose | 10% FBS 1% Sodium Pyruvate 1% Pen/Strep |
|
Efficient transcriptional gene activation using CRISPRa synthetic crRNA:tracrRNA in dCas9 expressing stable cell lines
Adherent dCas9-VPR Stable Cell Lines were plated at 10,000 cells/well and reverse transfected using DharmaFECT1 or DharmaFECT4 Transfection Reagent with a pool of synthetic crRNA:tracrRNAs(25 nM) targeting human TTN (Cat # U-009100-01-XX). Cells were harvested 72 hours post-transfection and the relative gene expression was measured using RT-qPCR. The relative fold transcriptional activation was calculated with the Cq method using GAPDH as the housekeeping gene and normalized to a non-targeting control (Cat # U-009500-01-XX).
Suspension K562 dCas9-VPR Stable Cell Line was electroporated using 100,000 cells/well, and Lonza buffer SF with a pool of synthetic crRNA:tracrRNAs(25 nM) targeting human TTN (Cat # U-009100-01-XX). Cells were harvested 72 hours post-transfection and the relative gene expression was measured using RT-qPCR. The relative fold transcriptional activation for was calculated with the Cq method using GAPDH as the housekeeping gene and normalized to a non-targeting control (Cat # U-009500-01-XX).